Day One Biopharmaceuticals (DAWN) EBIAT (2023 - 2025)
Historic EBIAT for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$19.7 million.
- Day One Biopharmaceuticals' EBIAT fell 15326.03% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.8 million, marking a year-over-year decrease of 8003.63%. This contributed to the annual value of -$95.5 million for FY2024, which is 4945.08% up from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' EBIAT is -$19.7 million, which was down 15326.03% from -$30.3 million recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' EBIAT ranged from a high of $37.0 million in Q3 2024 and a low of -$65.7 million during Q4 2024
- For the 3-year period, Day One Biopharmaceuticals' EBIAT averaged around -$32.8 million, with its median value being -$40.9 million (2023).
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 18025.35% in 2024, then crashed by 58804.18% in 2025.
- Quarter analysis of 3 years shows Day One Biopharmaceuticals' EBIAT stood at -$54.5 million in 2023, then dropped by 20.55% to -$65.7 million in 2024, then surged by 69.98% to -$19.7 million in 2025.
- Its EBIAT stands at -$19.7 million for Q3 2025, versus -$30.3 million for Q2 2025 and -$36.0 million for Q1 2025.